Retroperitoneal fibrosis during etanercept therapy for rheumatoid arthritis

Journal of Rheumatology

Volumn 40, Issue 11, 2013, Pages 1931-1933

  Couderc, Marion ^a   Mathieu, Sylvain ^a   Dubost, Jean Jacques ^a   Soubrier, Martin ^a  

^a UNIVERSITÉ CLERMONT AUVERGNE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ADALIMUMAB; C REACTIVE PROTEIN; CREATININE; CYCLOPHOSPHAMIDE; EPIRUBICIN; ETANERCEPT; FLUORODEOXYGLUCOSE F 18; FLUOROURACIL; LETROZOLE; METHOTREXATE; METHYLPREDNISOLONE; PERINDOPRIL; ROSUVASTATIN; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

ABSENCE OF SIDE EFFECTS; ADULT; ARTERY DISEASE; BREAST ADENOCARCINOMA; BREAST SURGERY; CANCER RADIOTHERAPY; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; DRUG MEGADOSE; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; FEVER; HUMAN; HUMAN TISSUE; HYDRONEPHROSIS; HYPERTENSION; IMMUNOSUPPRESSIVE TREATMENT; JJ STENT; KIDNEY BIOPSY; LETTER; LOW BACK PAIN; MALE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEINURIA; RETROPERITONEAL FIBROSIS; RHEUMATOID ARTHRITIS;

ARTHRITIS, RHEUMATOID; FEMALE; HUMANS; IMMUNOGLOBULIN G; MALE; MIDDLE AGED; RECEPTORS, TUMOR NECROSIS FACTOR; RETROPERITONEAL FIBROSIS;

EID: 84887448494     PISSN: 0315162X     EISSN: 14992752     Source Type: Journal    
DOI: 10.3899/jrheum.130324     Document Type: Letter

References (13)

1. Pipitone N, Vaglio A, Salvarani C. Retroperitoneal fibrosis. Best Pract Res Clin Rheumatol 2012;26:439-48.
2. Catanoso MG, Spaggiari L, Magnani L, Pipitone N, Versari A, Boiardi L, et al. Efficacy of infliximab in a patient with refractory idiopathic retroperitoneal fibrosis. Clin Exp Rheumatol 2012;30:776-8.
3. Vaglio A, Salvarani C, Buzio C. Retroperitoneal fibrosis. Lancet 2006; 367:21-7.
4. Khosroshahi A, Carruthers MN, Stone JH, Shinagare S, Sainani N, Hasserjian RP, et al. Rethinking Ormond's disease: "idiopathic" retroperitoneal fibrosis in the era of IgG4-related disease. Medicine 2013;92:82-91.
5. Furst DE, Wallis R, Broder M, Beenhouwer DO. Tumor necrosis factor antagonists: different kinetics and/or mechanisms of action may explain differences in the risk for developing granulomatous infection. Semin Arthritis Rheum 2006;36:159-67.
6. Massara A, Cavazzini L, La Corte R, Trotta F. Sarcoidosis appearing during anti-tumor necrosis factor alpha therapy: a new "class effect" paradoxical phenomenon. Two case reports and literature review. Semin Arthritis Rheum 2010;39:313-9.
7. Collamer AN, Guerrero KT, Henning JS, Battafarano DF. Psoriatic skin lesions induced by tumor necrosis factor antagonist therapy: a literature review and potential mechanisms of action. Arthritis Rheum 2008;59:996-1001.
8. Braun J, Baraliakos X, Listing J, Davis J, van der Heijde D, Haibel H, et al. Differences in the incidence of flares or new onset of inflammatory bowel diseases in patients with ankylosing spondylitis exposed to therapy with anti-tumor necrosis factor alpha agents. Arthritis Rheum 2007;57:639-47.
9. Wendling D, Paccou J, Berthelot JM, Flipo RM, Guillaume-Czitrom S, Prati C, et al. New onset of uveitis during anti-tumor necrosis factor treatment for rheumatic diseases. Semin Arthritis Rheum 2011;41:503-10.
10. Gaujoux-Viala C, Giampietro C, Gaujoux T, Ea HK, Prati C, Orcel P, et al. Scleritis: a paradoxical effect of etanercept? Etanercept-associated inflammatory eye disease. J Rheumatol 2012;39:233-9.
11. Molloy ES, Langford CA, Clark TM, Gota CE, Hoffman GS. Anti-tumour necrosis factor therapy in patients with refractory Takayasu arteritis: long-term follow-up. Ann Rheum Dis 2008;67:1567-9.
12. Mariani N, So A, Aubry-Rozier B. Two cases of Takayasu's arteritis occurring under anti-TNF therapy. Joint Bone Spine 2013;80:211-3.
13. Verhoeven F, Bossert M, Lohse-Walliser A, Balblanc JC. Aortitis during etanercept therapy for ankylosing spondylitis: finding the culprit. Joint Bone Spine 2012;79:524-6.